Compare Quest Diagnostics Inc (DGX) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares Silver Trust — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while iShares Silver Trust trades at $54.9 (market cap $29.02B). The key difference: Quest Diagnostics Inc and iShares Silver Trust are close in size by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares Silver Trust for 89 Days on average.
| DGX | SLV | |
|---|---|---|
Market Cap | $25.48B | $29.02B |
Volume | 941,866 | 16,510,334 |
Sector | Health | — |
52-Week High | $247.45 | $105.57 |
52-Week Low | $173.49 | $42.40 |
Typical Hold Time | 56 Days | 89 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
SLV trades at $54.85, up 1.91% with bearish technical signals from moving averages but oversold RSI readings. The ETF shows minimal operational activity with $0 revenue and $2.17M net income in 2024, while assets surged to $13.4B from previous years. Recent news highlights silver's volatility amid Fed policy uncertainty and rising Treasury yields.
Outlook remains cautious due to bearish technicals and macroeconomic pressures on precious metals. Investment opportunity exists for contrarian buyers given oversold conditions, but risks include continued Fed tightening and dollar strength. Silver's dual role as monetary and industrial metal adds volatility exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
